Comparison of Laboratory Test Results of Minimal-Residual Disease in Samples From Patients With Acute Myeloid Leukemia
|ClinicalTrials.gov Identifier: NCT01498302|
Recruitment Status : Completed
First Posted : December 23, 2011
Last Update Posted : July 11, 2016
RATIONALE: Diagnostic procedures that find residual disease may help predict if the disease will come back in patients diagnosed with acute myeloid leukemia.
PURPOSE: This research trial studies the comparison of laboratory test results for minimal residual disease in samples from patients with acute myeloid leukemia.
|Condition or disease||Intervention/treatment|
|Leukemia||Other: diagnostic laboratory biomarker analysis Other: flow cytometry|
- To promote harmonization between Cooperative Group Reference Laboratories conducting minimal-residual disease (MRD) evaluation of acute myeloid leukemia by flow cytometry.
OUTLINE: Archived bone marrow and blood samples, distributed to the Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B laboratories, are analyzed for leukemia-associated immunophenotype (LAIP) assays and minimal residual disease studies by flow cytometry. Results are then provided to the National Cancer Institute for assessment and comparability of test results.
|Study Type :||Observational|
|Estimated Enrollment :||10 participants|
|Official Title:||Interlaboratory Comparability Study of Residual Disease in Acute Myelogenous Leukemia|
|Study Start Date :||February 2012|
|Actual Primary Completion Date :||July 2016|
- Degree of concordance in the MRD assay results between laboratories
Biospecimen Retention: Samples With DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01498302
|Principal Investigator:||J. Milburn Jessup, MD||National Cancer Institute (NCI)|